Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Topical Triamcinolone Acetonide-Loaded Liposomes Formulation Used as an Adjuvant to Intravitreal Ranibizumab Therapy for Neovascular Age Related Macular Degeneration

Version 1 : Received: 11 June 2021 / Approved: 23 June 2021 / Online: 23 June 2021 (12:56:55 CEST)

A peer-reviewed article of this Preprint also exists.

Navarro-Partida, J.; Altamirano-Vallejo, J.C.; Aceves Franco, L.A.; Gonzalez-Cortes, J.; Hernandez-Da Mota, S.; García-Aguirre, J.G.; Azuara-Galindo, C.D.; Castro-Castaneda, C.R.; Armendariz-Borunda, J.; Santos, A. Topical Triamcinolone Acetonide-Loaded Liposome Formulation Used as an Adjuvant to Intravitreal Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration. Pharmaceutics 2021, 13, 1491. Navarro-Partida, J.; Altamirano-Vallejo, J.C.; Aceves Franco, L.A.; Gonzalez-Cortes, J.; Hernandez-Da Mota, S.; García-Aguirre, J.G.; Azuara-Galindo, C.D.; Castro-Castaneda, C.R.; Armendariz-Borunda, J.; Santos, A. Topical Triamcinolone Acetonide-Loaded Liposome Formulation Used as an Adjuvant to Intravitreal Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration. Pharmaceutics 2021, 13, 1491.

Journal reference: Pharmaceutics 2021, 13, 1491
DOI: 10.3390/pharmaceutics13091491

Abstract

Novel strategies have been developed to reduce or to avoid the intravitreal injections (IVTs) of the antiangiogenic (ranibizumab; RBZ) and the anti-inflammatory (triamcinolone acetonide; TA) agents used to treat vitreoretinal diseases. One of the strategies include liposomes. In this study, it was evaluated the safety and efficacy of topical triamcinolone-loaded liposomes formulation (TALF) as an adjuvant to intravitreal RBZ therapy in treatment-naive patients with neovascular age related macular degeneration (nAMD). Subjects were randomly assigned to the RBZ-TALF or the RBZ-pro re nata (RBZ-PRN) group. Patients from the RBZ-TALF group were instructed to apply TALF for a 12-month period after a single dose of RBZ. Patients from the RBZ-PRN group received three monthly RBZ-IVTs. Retreatment with RBZ was considered in case of nAMD reactivation. Related to safety, non-ocular abnormalities were observed during TALF therapy. Owing to the efficacy, non-significant differences are identified in visual acuity or central foveal thickness when the RBZ-PRN and RBZ-TALF groups are compared. Importantly the average number of RBZ injections was significantly lower in the RBZ-TALF group (2.5 ± 1.4 vs 6.1 ± 1.3 IVTs; p=0004). Therefore, TALF used as an adjuvant to RBZ reduce the number of RBZ-IVTs retreatment with optimal visual and anatomic results.

Keywords

Triamcinolone acetonide; Liposomes; Neovascular age related macular degeneration; Wet macular degeneration; Adjuvant therapy; Ranibizumab

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.